Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, presents exciting results from clinical trials for bispecific antibodies targeting BCMA at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France. Dr Usmani, explores the high efficacy and response rates observed in trials, where in a significant number of cases complete remission was also seen. As we expect more data on BCMA-targeting bispecfic antibody therapies at ASH 2018, Dr Usmani is excited at the prospects of this therapy in the relapsed/refractory setting.
Targeting BCMA with bispecific antibodies in R/R myeloma
